Price Alert

Monopar Therapeutics Inc. (MNPR)

NASDAQ: MNPR · Real-Time Price · USD

82.56

-7.86 (-8.69%)

At close: Oct 16, 2025, 3:59 PM

84.13

1.90%

After-hours: Oct 16, 2025, 06:40 PM EDT

-8.69% (1D)

Bid	77.77
Market Cap	509.39M
Revenue (ttm)	n/a
Net Income (ttm)	-1.32B
EPS (ttm)	-3.84
PE Ratio (ttm)	-21.5
Forward PE	-31.35
Analyst	Buy
Dividends	n/a

Ask	86.68
Volume	56,335
Avg. Volume (20D)	51,742
Open	89.67
Previous Close	90.42
Day's Range	81.53 - 93.50
52-Week Range	4.50 - 105.00
Beta	1.44
Ex-Dividend Date	n/a

About MNPR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MNPR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MNPR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

+14.73%

Monopar Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

2 months ago

+14.55%

Monopar Therapeutics shares are trading higher after the company reported a Q2 EPS beat.

News

1 month ago · investors.com

Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout

Monopar Therapeutics unveiled promising results Monday from three key studies, leading the top 1% biotech stock to break out of a cup base.

1 month ago · seekingalpha.com

Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent

Monopar Therapeutics Inc. is a clinical-stage biotech with two promising programs: ALXN1840 for Wilson disease and a radiopharmaceuticals pipeline targeting advanced cancers. ALXN1840 has shown superi...